Wang Chenghu, Cao Guofan, Xu Xiangzhong, Wang Jian, Zhang Shu
Affiliated Eye Hospital of Nanjing Medical University, Nanjing, China.
School of Communication Science and Disorders, Dalhousie University, Halifax, Canada.
Indian J Ophthalmol. 2021 Dec;69(12):3564-3569. doi: 10.4103/ijo.IJO_612_21.
To evaluate the outcome of the combined approach between intravitreal ranibizumab (IVR) and focal laser photocoagulation (FLP) in the treatment of symptomatic retinal arterial macroaneurysm (RAM).
A total of 10 patients were included in this clinical case series report. They were diagnosed with symptomatic RAM (one eye in each) and assessed by a comprehensive ophthalmologic examination, including fluorescein angiography (FA), optical coherence tomography angiography (OCT-A), and indocyanine green angiography (ICGA). All patients were treated with an IVR followed by an FLP 2 weeks later. If necessary, a second IVR was given 1 month after the first one (or 2 weeks after the first FLP), which was followed by a second FLP treatment 2 weeks later in the needed cases. All cases were followed up for 6 months after the last treatment.
Both the retina hemorrhage and edema were resolved by the treatment. No ocular and/or systemic side effects were evident, and no recrudescence of RAM was seen within the 6 months of follow-up.
The combined treatment of IVRs and FLPs was successful in the management of symptomatic RAM.
评估玻璃体内注射雷珠单抗（IVR）与局部激光光凝（FLP）联合治疗有症状性视网膜动脉大动脉瘤（RAM）的疗效。
本临床病例系列报告共纳入10例患者。他们被诊断为有症状性RAM（每例一只眼），并通过全面的眼科检查进行评估，包括荧光素血管造影（FA）、光学相干断层扫描血管造影（OCT - A）和吲哚菁绿血管造影（ICGA）。所有患者先接受IVR治疗，2周后再进行FLP治疗。如有必要，在首次IVR治疗1个月后（或首次FLP治疗2周后）给予第二次IVR治疗，必要时在2周后进行第二次FLP治疗。所有病例在最后一次治疗后随访6个月。
治疗后视网膜出血和水肿均消退。未发现明显的眼部和/或全身副作用，随访6个月内未见RAM复发。
IVR与FLP联合治疗有症状性RAM取得了成功。
